Arizona · 81291

Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants in Arizona

Arizona Medicare Avg
$64.03
0% above national avg
National Medicare Avg
$63.93
All states combined
Billed Charge (AZ)
$200.81
What providers submit
Est. Commercial (AZ)
$145.99
National avg: $143.20
Est. Cash / Self-Pay (AZ)
$103.24
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

61
Services in AZ
3
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Arizona

Provider Medicare Services
Genetic Technological Innovations,... $64.03 59

Arizona Pricing in Context

In Arizona, CPT code 81291 (Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants) carries an average Medicare payment of $64.03 — 0% above the national benchmark of $63.93. 3 providers across the state submitted claims for this procedure in 2023, performing 61 total services. Individual payments in AZ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Arizona is $200.81, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Arizona sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Arizona lands near $145.99, with self-pay cash prices typically around $103.24. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants cost in Arizona?

The average Medicare payment for Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants in Arizona is $64.03, which is 0% above the national average of $63.93. Providers in AZ typically bill $200.81 for this procedure.

What does Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants cost with insurance in Arizona?

With commercial insurance in Arizona, Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants costs an estimated $145.99. Without insurance, the estimated cash price is $103.24. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants in Arizona?

3 providers in Arizona billed Medicare for Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants in 2023, performing 61 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants cheaper in Arizona than the national average?

No — Gene Analysis (5, 10-Methylenetetrahydrofolate Reductase) Common Variants costs 0% above the national average in Arizona. The state average Medicare payment is $64.03 compared to $63.93 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial